The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
Abstract
Purpose: To evaluate the influence of adjuvant tamoxifen and exemestane on cognitive functioning in postmenopausal patients with breast cancer (BC). Patients and Methods: Neuropsychological assessments were performed before the start (T1) and after 1 year of adjuvant endocrine treatment (T2) in Dutch postmenopausal patients with BC, who did not receive chemotherapy. Patients participated in the international Tamoxifen and Exemestane Adjuvant Multinational trial, a prospective randomized study investigating tamoxifen versus exemestane as adjuvant therapy for hormone-sensitive BC. Results: Participants included 80 tamoxifen users (mean age, 68.7 years; range 51 to 84), 99 exemestane users (mean age, 68.3 years; range, 50 to 82), and 120 healthy controls (mean age, 66.2 years; range, 49 to 86). At T2, after adjustment for T1 performance, exemestane users did not perform statistically significantly worse than healthy controls on any cognitive domain. In contrast, tamoxifen users performed statistically significantly worse than healthy controls on verbal memory (P < .01; Cohen's d = .43) and executive functioning (P = .01; Cohen's d = .40), and statistically significantly worse than exemestane users on information processing speed (P = .02; Cohen's d = .36). With respect to visual memory, working memory, verbal fluency, reaction speed, and motor speed, no significant differences between the three groups were found. Conclusion: After 1 year of adjuvant therapy, tamoxifen use is associated with statistically significant lower functioning in verbal memory and executive functioning, whereas exemestane use is not associated with statistically significant lower cognitive functioning in postmenopausal patients with BC. Our results accentuate the need to include assessments of cognitive effects of adjuvant endocrine treatment in long-term safety studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Validity of the Trail Making Test as an Indicator of Organic Brain Damage
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 7,928
The Neuropsychological Assessment
Ogden, J. A. (2005) · Fractured Minds · doi:10.1093/oso/9780195171358.003.0002 · Cited by 4,364
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_302294 · Cited by 2,278
Comparative distribution of estrogen receptor-? and -? mRNA in the rat central nervous system
Shughrue, P. J., Lane, M. V., & Merchenthaler, I. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19971201)388:4<507::aid-cne1>3.0.co;2-6 · Cited by 2,259
Reynolds, C. R., & Powel, J. (1988) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/3.4.397 · Cited by 2,095
Estrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,320
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Cited by
Prevalence, mechanisms, and management of cancer-related cognitive impairment
Janelsins, M. C., Kesler, S. R., Ahles, T. A., & Morrow, G. R. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.864260 · Cited by 745
Cancer- and Cancer Treatment–Associated Cognitive Change: An Update on the State of the Science
Ahles, T. A., Root, J. C., & Ryan, E. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0116 · Cited by 704
Ahles, T. A., Saykin, A. J., McDonald, B. C., Li, Y., Furstenberg, C. T., Hanscom, B. S., Mulrooney, T. J., Schwartz, G. N., & Kaufman, P. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0827 · Cited by 535
Wefel, J. S., Kesler, S. R., Noll, K. R., & Schagen, S. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21258 · Cited by 532
Self-citationJim, H. S. L., Phillips, K. M., Chait, S., Faul, L. A., Popa, M. A., Lee, Y.-H., Hussin, M. G., Jacobsen, P. B., & Small, B. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5640 · Cited by 410
Metadata
- Authors
- Schilder, C. M., Seynaeve, C., Beex, L. V., Boogerd, W., Linn, S. C., Gundy, C. M., Huizenga, H. M., Nortier, J. W., van de Velde, C. J., van Dam, F. S., & Schagen, S. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-03-10
- Volume
- 28
- Issue
- 8
- Pages
- 1294-1300
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150329556
- Cited by
- 269
- References
- 43
- FWCI
- 16.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial. https://app.cochat.ai/papers/10.1200/jco.2008.21.3553
- The paper
- Schilder, C. M., Seynaeve, C., Beex, L. V., Boogerd, W., Linn, S. C., Gundy, C. M., Huizenga, H. M., Nortier, J. W., van de Velde, C. J., van Dam, F. S., & Schagen, S. B. (2010). Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.3553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.